Total symptomatic DENV infections reported by the Ministry of Health and estimated episodes using expansion factors from the Morelos cohort study.

Notes: Estimated cases from the Mexican Ministry of Health (MoH) include all lab-confirmed cases plus the share of positive cases from the laboratory diagnosed samples multiplied by the probable cases reported (probable dengue are suspected episodes of dengue with specific clinical symptoms). 95%CL denotes a 95% certainty level for each estimate, obtained through Monte Carlo simulations using the probability distributions shown in Table 5. These numbers in parentheses indicate the region of uncertainty around base-case estimates. DENV denotes dengue virus, DF denotes dengue fever, DHF denotes dengue hemorrhagic fever, EF denotes expansion factor, CL denotes certainty level.
a In year 2011, 13.7% of the DF episodes and 3.1% of the DHF episodes reported by the MoH were not classified as ambulatory or hospitalized cases in the data. We assigned these patients to hospitalized or ambulatory treatments based on the proportion of patients by treatment in 2010.
Total symptomatic DENV infections reported by the Ministry of Health and estimated episodes using expansion factors from the Morelos cohort study.

备注：墨西哥卫生部（Mexican Ministry of Health, MoH）统计的估算病例数，涵盖所有实验室确诊病例，加上经实验室检测样本阳性率乘以报告的疑似病例所得的对应份额（疑似登革热（probable dengue）指伴有特定临床症状的疑似登革热发作病例）。95%置信水平（95%CL）指各项估算的95%置信水平，通过采用表5所示概率分布开展蒙特卡洛模拟（Monte Carlo simulations）得到。括号内的数值表示基准估算值的不确定性区间。其中，DENV指代登革病毒（DENV），DF指代登革热（DF），DHF指代登革出血热（DHF），EF指代扩展因子（EF），CL指代置信水平（CL）。
a 2011年，该卫生部报告的登革热（DF）发作病例中有13.7%、登革出血热（DHF）发作病例中有3.1%未在数据中被归类为门诊或住院病例。我们依据2010年不同治疗方式的患者占比，将此类患者分配至住院或门诊治疗组别。
本数据集涵盖墨西哥卫生部报告的有症状登革病毒（DENV）感染总例数，以及采用莫雷洛斯队列研究（Morelos cohort study）所得扩展因子（EF）估算的登革热发作例数。